logo-loader

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions

Published: 23:00 18 May 2017 BST

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
Paul Rennie, chief executive officer, Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, joined Proactive's CEO Sessions in Melbourne on Tuesday 16th May and Sydney on Wednesday 17th May.

Paradigm has results from its Phase 2 hay fever trial pending in six weeks.

ACCESS THE FULL PRESENTATION HERE

HANetf founder and co-CEO discusses shift to active management in ETF market

HANetf founder and co-CEO Hector McNeil tells Proactive's Stephen Gunnion about shifting trends in the exchange-traded fund (ETF) market in the United States, indicating a big move towards active management within ETFs. Despite the European market lagging behind the US by three to five years,...

12 hours, 19 minutes ago